Chardan Capital Reiterates a Buy Rating on Caladrius Biosciences (CLBS)

By Austin Angelo

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Caladrius Biosciences (CLBSResearch Report), with a price target of $6.00. The company’s shares closed last Thursday at $1.70.

According to, Nakae is a 4-star analyst with an average return of 5.8% and a 48.2% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Lineage Cell Therapeutics, and Emergent Biosolutions.

Currently, the analyst consensus on Caladrius Biosciences is a Moderate Buy with an average price target of $12.25, representing a 464.5% upside. In a report issued on May 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.50 price target.

See today’s analyst top recommended stocks >>

Based on Caladrius Biosciences’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $3.99 million. In comparison, last year the company had a GAAP net loss of $4.37 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.